Gail Boxer Marcus Sells 500 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA – Get Free Report) Director Gail Boxer Marcus sold 500 shares of the stock in a transaction on Friday, December 8th. The shares were sold at an average price of $57.52, for a total value of $28,760.00. Following the completion of the transaction, the director now directly owns 20,146 shares of the company’s stock, valued at $1,158,797.92. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Gail Boxer Marcus also recently made the following trade(s):

On Tuesday, November 21st, Gail Boxer Marcus sold 1,000 shares of Natera stock. The shares were sold at an average price of $54.31, for a total value of $54,310.00. Natera Stock Performance

NTRA traded up $1.82 during trading on Tuesday, hitting $58.52. 1,103,301 shares of the stock were exchanged, compared to its average volume of 1,222,909. The stock has a fifty day moving average price of $47.85 and a two-hundred day moving average price of $49.64. Natera, Inc. has a 1-year low of $35.02 and a 1-year high of $63.00. The firm has a market capitalization of $7.03 billion, a P/E ratio of -12.95 and a beta of 1.33. The company has a quick ratio of 4.23, a current ratio of 4.37 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRA – Get Free Report) last announced its earnings results on Wednesday, November 8th. The medical research company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.01. Natera had a negative return on equity of 72.98% and a negative net margin of 50.50%. The company had revenue of $268.30 million for the quarter, compared to the consensus estimate of $259.27 million. During the same period last year, the business posted ($1.25) EPS. The company’s revenue was up 27.4% on a year-over-year basis. As a group, sell-side analysts predict that Natera, Inc. will post -3.92 earnings per share for the current year.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently bought and sold shares of the company. American Century Companies Inc. raised its holdings in Natera by 115.7% during the third quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company’s stock worth $73,203,000 after purchasing an additional 887,409 shares during the last quarter. Banque Pictet & Cie SA increased its stake in Natera by 7.3% in the third quarter. Banque Pictet & Cie SA now owns 142,850 shares of the medical research company’s stock valued at $6,321,000 after purchasing an additional 9,755 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Natera by 382.2% during the third quarter. The Manufacturers Life Insurance Company now owns 21,511 shares of the medical research company’s stock valued at $952,000 after acquiring an additional 17,050 shares during the period. Royal Bank of Canada grew its position in Natera by 0.3% during the third quarter. Royal Bank of Canada now owns 83,843 shares of the medical research company’s stock valued at $3,710,000 after acquiring an additional 245 shares during the period. Finally, RTW Investments LP grew its position in Natera by 1.5% during the third quarter. RTW Investments LP now owns 2,651,783 shares of the medical research company’s stock valued at $117,341,000 after acquiring an additional 40,000 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have issued reports on NTRA. Piper Sandler dropped their target price on Natera from $80.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, October 16th. Morgan Stanley lowered their target price on Natera from $70.00 to $68.00 and set an “overweight” rating for the company in a report on Friday, November 10th. Sanford C. Bernstein started coverage on Natera in a research report on Thursday, September 28th. They issued a “market perform” rating and a $48.00 price target on the stock. StockNews.com started coverage on Natera in a research report on Thursday, October 5th. They issued a “sell” rating on the stock. Finally, UBS Group cut their target price on Natera from $76.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $66.56.

Get Our Latest Stock Report on Natera

About Natera (Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

You may also like

Caspian Sunrise PLC shares soar as early flows from Deep Well A5 impress

Burberry shares sink as luxury spending slowdown bites

Charger Metals shares dip after Rio Tinto deal on Lake Johnston Lithium Project By Investing.com